Hundreds of Paxil Birth Defect Cases Reported Settled

By: Alberto Stellpflug | Posted: 06th July 2010

(1888PressRelease) Court documents confirm the settlement of hundreds of Paxil birth defect cases pending in the mass tort program in Philadelphia.

New York, NY - An order signed on June 15, 2010 by Justice Sandra Moss, has paved the way for the settlement of of hundreds of Paxil birth defect cases pending against GlaxoSmithKline, GSK. No Paxil birth defect cases have been tried since the October 13, 2009, verdict where a jury awarded $2.5M to the family of Lyam Kilker, a child born with a congenital heart defect caused by Paxil use during pregnancy.

Approximately 600 cases have been filed against GSK, most in the Mass Tort Program in the Court of Common Pleas in Philadelphia. It has been reported by the Legal Intelligencer that Judge Moss, the coordinating judge of Philadelphia's mass tort program, the Complex Litigation Center, said the philosophy of GSK "is to try and settle what they can and to settle in groups."

While hundreds of cases may have been settled, many more may be filed. Parents who took Paxil during pregnancy and gave birth to a child with a congenital heart defect should act quickly to determine whether they my file a claim on behalf of their child.

Parents may visit for more information.

The most common injuries caused by Paxil are:

Heart Birth Defects (Pulmonary Stenosis, Pulmonary Atresia, Atrial or Ventricular Septal Defects, Murmurs, etc)
Lung Birth Defects (Persistent Pulmonary Hypertension)
Craniosynostosis (resulting in an abnormally shaped head)
Abdominal Birth Defects (Omphalocele)
Cranial Birth Defects (Craniosynostosis)

If you or someone you know had a child who was born with a congenital heart defect or other birth defect, and the child was exposed to Paxil (paroxetine) during pregnancy, they may be entitled to significant compensation. For more information go to

This article is free for republishing
Printed From:

Back to the original article

Tags: hypertension, birth defects, glaxosmithkline, 5m